Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Authors
Keywords
-
Journal
Cancers
Volume 10, Issue 4, Pages 99
Publisher
MDPI AG
Online
2018-03-31
DOI
10.3390/cancers10040099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study
- (2017) Yael P. Mossé et al. JOURNAL OF CLINICAL ONCOLOGY
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
- (2017) Alice T Shaw et al. LANCET ONCOLOGY
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
- (2017) Solange Peters et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma
- (2017) Charlotte Rigaud et al. PEDIATRIC BLOOD & CANCER
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety
- (2016) Thomas S. Y. Chan et al. ANNALS OF HEMATOLOGY
- Nivolumab for Refractory Anaplastic Large Cell Lymphoma: A Case Report
- (2016) Holger Hebart et al. ANNALS OF INTERNAL MEDICINE
- Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10
- (2016) I. Kiss et al. ANNALS OF ONCOLOGY
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- Paediatric non-Hodgkin lymphoma - perspectives in translational biology
- (2016) Bruce Shiramizu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Anaplastic large cell lymphoma in paediatric and young adult patients
- (2016) Suzanne D. Turner et al. BRITISH JOURNAL OF HAEMATOLOGY
- First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium
- (2016) Frank M. Balis et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib
- (2016) Carlo Gambacorti-Passerini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Ceritinib in patients with advanced anaplastic lymphoma kinase-rearranged anaplastic large-cell lymphoma
- (2015) H. Richly et al. BLOOD
- Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
- (2015) Andres Forero-Torres et al. BLOOD
- Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas
- (2015) Michela Boi et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
- (2015) Frederick H. Wilson et al. CANCER CELL
- Novel immunotherapies in lymphoid malignancies
- (2015) Connie Lee Batlevi et al. Nature Reviews Clinical Oncology
- Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
- (2014) A. K. Gopal et al. BLOOD
- Haematopoietic stem cell transplantation for relapsed or refractory anaplastic large cell lymphoma: a study of children and adolescents in Japan
- (2014) Reiji Fukano et al. BRITISH JOURNAL OF HAEMATOLOGY
- Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients
- (2014) Carlo Gambacorti Passerini et al. JNCI-Journal of the National Cancer Institute
- Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group
- (2014) Sarah Alexander et al. PEDIATRIC BLOOD & CANCER
- The Management of Brain Metastases in Non-Small Cell Lung Cancer
- (2014) Scott Owen et al. Frontiers in Oncology
- CD30 as a Therapeutic Target for Lymphoma
- (2013) Thomas Schirrmann et al. BIODRUGS
- Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma
- (2013) C. Damm-Welk et al. BLOOD
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- (2013) Yael P Mossé et al. LANCET ONCOLOGY
- Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy
- (2013) Ajay K. Gopal et al. LEUKEMIA & LYMPHOMA
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- (2012) D Ross Camidge et al. LANCET ONCOLOGY
- Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
- (2012) L Mussolin et al. LEUKEMIA
- PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas
- (2012) Daniela Laimer et al. NATURE MEDICINE
- Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma
- (2011) A. Attarbaschi et al. BLOOD
- Relapsed or Refractory Anaplastic Large-Cell Lymphoma in Children and Adolescents After Berlin-Frankfurt-Muenster (BFM)–Type First-Line Therapy: A BFM-Group Study
- (2011) Willi Woessmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
- (2011) O. Merkel et al. MOLECULAR CANCER THERAPEUTICS
- Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: Report of the ALCL99 randomised trial
- (2011) Grazyna Wrobel et al. PEDIATRIC BLOOD & CANCER
- Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk
- (2010) K. Ait-Tahar et al. BLOOD
- Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial
- (2010) Marie-Cécile Le Deley et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
- (2009) Ryo Yamamoto et al. CANCER SCIENCE
- Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology
- (2009) Laurence Brugières et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group
- (2009) Laurence Brugières et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: A report of the Italian Association of pediatric hematology and oncology
- (2009) Marta Pillon et al. PEDIATRIC BLOOD & CANCER
- The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
- (2008) Roberto Chiarle et al. NATURE MEDICINE
- Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941
- (2008) Eric J. Lowe et al. PEDIATRIC BLOOD & CANCER
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now